{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:22:37Z","timestamp":1793643757286,"version":"4.5.1"},"reference-count":63,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,5,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Approximately 80% of adult patients with immune thrombocytopenia (ITP) have treatment failure with corticosteroids or become dependent on them and require second-line therapy. Several new and effective therapies have been introduced during the past decade and our understanding of disease burden and its effect on quality of life has expanded. It is now recommended that splenectomy, the standard second-line therapy for decades, be delayed for at least 12 to 24 months, allowing for more patients to achieve remission on medical therapies before considering surgery. It is highly recommended that medical therapies be used that have abundant clinical trial evidence, such as the thrombopoietin receptor agonists (TPO-RAs) rituximab and fostamatinib. Unfortunately, there are no reliable biomarkers that help in treatment selection. These therapeutic medical options have variable efficacy, safety profiles, mechanisms of action, and modes of administration. This enables and mandates an individualized approach to treatment, where patient involvement, preferences and values have become central to the process of choosing the appropriate therapy. Both TPO-RAs and fostamatinib are maintenance therapies, whereas rituximab is given for a limited number of doses. Although the response is usually maintained while receiving a TPO-RA or fostamatinib therapy, half of rituximab responders will no longer respond 1 to 2 years after administration and require retreatment or other therapy.<\/jats:p>","DOI":"10.1182\/blood.2021010968","type":"journal-article","created":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T20:11:47Z","timestamp":1617826307000},"page":"2736-2744","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":62,"title":["How I treat primary ITP in adult patients who are unresponsive to or dependent on corticosteroid treatment"],"prefix":"10.1182","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2225-6165","authenticated-orcid":false,"given":"Waleed","family":"Ghanima","sequence":"first","affiliation":[{"name":"Department of Hemato-Oncology and"},{"name":"Department of Research, \u00d8stfold Hospital, Kalnes, Norway;"},{"name":"Department of Hematology, Oslo University Hospital\u2013Institute of Clinical Medicine, University of Oslo, Oslo, Norway;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Gernsheimer","sequence":"additional","affiliation":[{"name":"Division of Hematology, University of Washington, Seattle, WA;"},{"name":"Seattle Cancer Care Alliance, Seattle, WA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Kuter","sequence":"additional","affiliation":[{"name":"Division of Hematology, Massachusetts General Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"2","key":"2021052015231448400_B1","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2141.2009.07615.x","article-title":"Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database","volume":"145","author":"Schoonen","year":"2009","journal-title":"Br J Haematol"},{"key":"2021052015231448400_B2","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.eclinm.2019.07.015","article-title":"Chronic immune thrombocytopenia in Denmark, Sweden and Norway: The Nordic Country Patient Registry for Romiplostim","volume":"14","author":"Christiansen","year":"2019","journal-title":"EClinicalMedicine"},{"issue":"11","key":"2021052015231448400_B3","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"issue":"10","key":"2021052015231448400_B4","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1056\/NEJMcp1810479","article-title":"Immune thrombocytopenia","volume":"381","author":"Cooper","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"2021052015231448400_B5","first-page":"1","article-title":"Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura","volume":"38","author":"Harrington","year":"1951","journal-title":"J Lab Clin Med"},{"issue":"15","key":"2021052015231448400_B6","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1056\/NEJM198904133201505","article-title":"Mechanisms of response to treatment in autoimmune thrombocytopenic purpura","volume":"320","author":"Gernsheimer","year":"1989","journal-title":"N Engl J Med"},{"issue":"6","key":"2021052015231448400_B7","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/MOH.0000000000000612","article-title":"An update on the pathophysiology of immune thrombocytopenia","volume":"27","author":"Semple","year":"2020","journal-title":"Curr Opin Hematol"},{"issue":"22","key":"2021052015231448400_B8","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv"},{"issue":"23","key":"2021052015231448400_B9","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia [published correction appears in Blood Adv. 2020;4:252]","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv"},{"issue":"3","key":"2021052015231448400_B10","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s12185-019-02790-z","article-title":"Reference guide for management of adult immune thrombocytopenia in Japan: 2019 Revision","volume":"111","author":"Kashiwagi","year":"2020","journal-title":"Int J Hematol"},{"issue":"suppl 5","key":"2021052015231448400_B11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000492187","article-title":"Immune thrombocytopenia - current diagnostics and therapy: recommendations of a joint working group of DGHO, \u00d6GHO, SGH, GPOH, and DGTI","volume":"41","author":"Matzdorff","year":"2018","journal-title":"Oncol Res Treat"},{"issue":"6","key":"2021052015231448400_B12","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1182\/blood.V64.6.1179.1179","article-title":"Therapeutic experience on 934 adults with idiopathic thrombocytopenic purpura: Multicentric Trial of the Cooperative Latin American group on Hemostasis and Thrombosis","volume":"64","author":"Pizzuto","year":"1984","journal-title":"Blood"},{"issue":"12","key":"2021052015231448400_B13","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1002\/ajh.25989","article-title":"High-dose dexamethasone plus recombinant human thrombopoietin vs high-dose dexamethasone alone as frontline treatment for newly diagnosed adult primary immune thrombocytopenia: a prospective, multicenter, randomized trial","volume":"95","author":"Yu","year":"2020","journal-title":"Am J Hematol"},{"issue":"11","key":"2021052015231448400_B14","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1182\/blood-2012-09-455691","article-title":"Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia","volume":"121","author":"Gudbrandsdottir","year":"2013","journal-title":"Blood"},{"issue":"14","key":"2021052015231448400_B15","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1182\/blood-2009-07-229815","article-title":"Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia","volume":"115","author":"Zaja","year":"2010","journal-title":"Blood"},{"issue":"9","key":"2021052015231448400_B16","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1111\/jth.14227","article-title":"Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults","volume":"16","author":"Piel-Julian","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2021052015231448400_B17","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1111\/jth.14446","article-title":"Cardiovascular and bleeding outcomes in a population-based cohort of patients with chronic immune thrombocytopenia","volume":"17","author":"Adelborg","year":"2019","journal-title":"J Thromb Haemost"},{"issue":"14","key":"2021052015231448400_B18","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1182\/blood-2012-07-442392","article-title":"Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group","volume":"121","author":"Rodeghiero","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2021052015231448400_B19","first-page":"829","article-title":"Assessment of a therapeutic strategy for adults with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than platelet count","volume":"90","author":"Khellaf","year":"2005","journal-title":"Haematologica"},{"issue":"2","key":"2021052015231448400_B20","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2141.2007.06635.x","article-title":"The immune thrombocytopenic purpura (ITP) bleeding score: assessment of bleeding in patients with ITP","volume":"138","author":"Page","year":"2007","journal-title":"Br J Haematol"},{"issue":"20","key":"2021052015231448400_B21","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1002625","article-title":"Romiplostim or standard of care in patients with immune thrombocytopenia","volume":"363","author":"Kuter","year":"2010","journal-title":"N Engl J Med"},{"issue":"9763","key":"2021052015231448400_B22","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0140-6736(10)60959-2","article-title":"Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study","volume":"377","author":"Cheng","year":"2011","journal-title":"Lancet"},{"issue":"5","key":"2021052015231448400_B23","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/ajh.23163","article-title":"Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care","volume":"87","author":"Kuter","year":"2012","journal-title":"Am J Hematol"},{"issue":"2","key":"2021052015231448400_B24","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/ajh.26045","article-title":"Immune thrombocytopenia (ITP) World Impact Survey (iWISh): Patient and physician perceptions of diagnosis, signs and symptoms, and treatment","volume":"96","author":"Cooper","year":"2021","journal-title":"Am J Hematol"},{"issue":"23","key":"2021052015231448400_B25","doi-asserted-by":"crossref","first-page":"4782","DOI":"10.1182\/blood-2012-12-467068","article-title":"Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia","volume":"121","author":"Boyle","year":"2013","journal-title":"Blood"},{"issue":"9","key":"2021052015231448400_B26","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1182\/blood-2004-03-1168","article-title":"Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications","volume":"104","author":"Kojouri","year":"2004","journal-title":"Blood"},{"issue":"7","key":"2021052015231448400_B27","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.3324\/haematol.2013.103291","article-title":"Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration","volume":"99","author":"Bussel","year":"2014","journal-title":"Haematologica"},{"issue":"4","key":"2021052015231448400_B28","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/ejh.12839","article-title":"Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response","volume":"98","author":"Marangon","year":"2017","journal-title":"Eur J Haematol"},{"issue":"2","key":"2021052015231448400_B29","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1080\/09537104.2020.1745168","article-title":"Thrombopoietin receptor agonists for the treatment of primary immune thrombocytopenia: a meta-analysis and systematic review","volume":"32","author":"Birocchi","year":"2021","journal-title":"Platelets"},{"issue":"6","key":"2021052015231448400_B30","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.3324\/haematol.2018.212845","article-title":"Thrombopoietin receptor agonists: ten years later","volume":"104","author":"Ghanima","year":"2019","journal-title":"Haematologica"},{"issue":"3","key":"2021052015231448400_B31","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/bjh.15573","article-title":"Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia","volume":"183","author":"Jurczak","year":"2018","journal-title":"Br J Haematol"},{"issue":"2","key":"2021052015231448400_B32","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/bjh.13827","article-title":"Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study","volume":"172","author":"Newland","year":"2016","journal-title":"Br J Haematol"},{"issue":"3","key":"2021052015231448400_B33","doi-asserted-by":"crossref","first-page":"E40","DOI":"10.1002\/ajh.23900","article-title":"Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia","volume":"90","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Am J Hematol"},{"issue":"6","key":"2021052015231448400_B34","doi-asserted-by":"crossref","first-page":"881","DOI":"10.3324\/haematol.2012.074633","article-title":"A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia","volume":"98","author":"Khellaf","year":"2013","journal-title":"Haematologica"},{"issue":"1","key":"2021052015231448400_B35","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/ajh.24935","article-title":"Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers","volume":"93","author":"Cantoni","year":"2018","journal-title":"Am J Hematol"},{"issue":"3","key":"2021052015231448400_B36","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s12185-014-1731-7","article-title":"Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim","volume":"101","author":"Kuter","year":"2015","journal-title":"Int J Hematol"},{"issue":"7","key":"2021052015231448400_B37","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1007\/s00277-016-2682-2","article-title":"Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia","volume":"95","author":"Janssens","year":"2016","journal-title":"Ann Hematol"},{"issue":"5","key":"2021052015231448400_B38","doi-asserted-by":"crossref","first-page":"937","DOI":"10.3324\/haematol.2013.098921","article-title":"Bone marrow fibrosis in 66 Immune Thrombocytopenia patients treated with thrombopoietin receptor agonists: a single center long-term follow-up","volume":"99","author":"Ghanima","year":"2014","journal-title":"Haematologica"},{"issue":"2","key":"2021052015231448400_B39","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1159\/000452992","article-title":"A 2-year longitudinal, prospective study of the effects of eltrombopag on bone marrow in patients with chronic immune thrombocytopenia","volume":"137","author":"Brynes","year":"2017","journal-title":"Acta Haematol"},{"issue":"7","key":"2021052015231448400_B40","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/ajh.24011","article-title":"Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: Data from the EXTEND study","volume":"90","author":"Brynes","year":"2015","journal-title":"Am J Hematol"},{"issue":"1","key":"2021052015231448400_B41","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/ajh.24234","article-title":"Is ITP a thrombophilic disorder?","volume":"91","author":"Rodeghiero","year":"2016","journal-title":"Am J Hematol"},{"issue":"12","key":"2021052015231448400_B42","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1080\/17474086.2020.1850253","article-title":"Romiplostim in adults with newly diagnosed or persistent immune thrombocytopenia","volume":"13","author":"Lozano","year":"2020","journal-title":"Expert Rev Hematol"},{"issue":"3","key":"2021052015231448400_B43","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1080\/14656566.2020.1841748","article-title":"An evaluation of avatrombopag for the treatment of thrombocytopenia","volume":"22","author":"Virk","year":"2020","journal-title":"Expert Opin Pharmacother"},{"issue":"7","key":"2021052015231448400_B44","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.25125","article-title":"Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials","volume":"93","author":"Bussel","year":"2018","journal-title":"Am J Hematol"},{"key":"2021052015231448400_B45","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S2352-3026(15)00003-4","article-title":"The efficacy and safety of rituximab for the treatment of adults with primary immune thrombocytopenia: systematic review and meta-analysis","volume":"2","author":"Chugh","year":"2015","journal-title":"Lancet Haematol"},{"issue":"1","key":"2021052015231448400_B46","doi-asserted-by":"crossref","first-page":"25","DOI":"10.7326\/0003-4819-146-1-200701020-00006","article-title":"Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura","volume":"146","author":"Arnold","year":"2007","journal-title":"Ann Intern Med"},{"issue":"6","key":"2021052015231448400_B47","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3324\/haematol.2019.218883","article-title":"Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019?","volume":"104","author":"Lucchini","year":"2019","journal-title":"Haematologica"},{"issue":"12","key":"2021052015231448400_B48","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/ajh.25632","article-title":"Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5\u2009years from the French prospective registry ITP-ritux","volume":"94","author":"Deshayes","year":"2019","journal-title":"Am J Hematol"},{"issue":"3","key":"2021052015231448400_B49","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/bjh.16672","article-title":"Long-term outcomes of patients treated with rituximab as second-line treatment for adult immune thrombocytopenia - Follow-up of the RITP study","volume":"191","author":"Tj\u00f8nnfjord","year":"2020","journal-title":"Br J Haematol"},{"issue":"1","key":"2021052015231448400_B50","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/art.25033","article-title":"Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab","volume":"62","author":"van Assen","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2021052015231448400_B51","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/bjh.15090","article-title":"A critical appraisal of the evidence for the role of splenectomy in adults and children with ITP","volume":"181","author":"Rodeghiero","year":"2018","journal-title":"Br J Haematol"},{"issue":"6","key":"2021052015231448400_B52","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/bjh.16959","article-title":"Fostamatinib is an effective second-line therapy in patients with immune thrombocytopenia","volume":"190","author":"Boccia","year":"2020","journal-title":"Br J Haematol"},{"issue":"22","key":"2021052015231448400_B53","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1182\/blood-2014-06-582346","article-title":"Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients","volume":"124","author":"Khellaf","year":"2014","journal-title":"Blood"},{"issue":"12","key":"2021052015231448400_B54","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.3324\/haematol.11709","article-title":"Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults","volume":"92","author":"Provan","year":"2007","journal-title":"Haematologica"},{"issue":"5","key":"2021052015231448400_B55","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/blood-2010-07-295444","article-title":"Pregnancy outcomes after maternal exposure to rituximab","volume":"117","author":"Chakravarty","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2021052015231448400_B56","doi-asserted-by":"crossref","first-page":"rkaa074","DOI":"10.1093\/rap\/rkaa074","article-title":"Pregnancy outcomes following maternal treatment with rituximab prior to or during pregnancy: a case series","volume":"5","author":"Perrotta","year":"2021","journal-title":"Rheumatol Adv Pract"},{"issue":"4","key":"2021052015231448400_B57","doi-asserted-by":"crossref","first-page":"e734","DOI":"10.1212\/NXI.0000000000000734","article-title":"Rituximab, MS, and pregnancy","volume":"7","author":"Smith","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"2","key":"2021052015231448400_B58","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s12185-019-02638-6","article-title":"Glucocorticoids promote response to thrombopoietin-receptor agonists in refractory ITP: a case series","volume":"110","author":"Poston","year":"2019","journal-title":"Int J Hematol"},{"issue":"9","key":"2021052015231448400_B59","doi-asserted-by":"crossref","first-page":"e640","DOI":"10.1016\/S2352-3026(20)30227-1","article-title":"Perioperative oral eltrombopag versus intravenous immunoglobulin in patients with immune thrombocytopenia: a non-inferiority, multicentre, randomised trial","volume":"7","author":"Arnold","year":"2020","journal-title":"Lancet Haematol"},{"issue":"1","key":"2021052015231448400_B60","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/bjh.15280","article-title":"Romiplostim for the management of perioperative thrombocytopenia","volume":"182","author":"Al-Samkari","year":"2018","journal-title":"Br J Haematol"},{"issue":"7","key":"2021052015231448400_B61","doi-asserted-by":"crossref","first-page":"E170","DOI":"10.1002\/ajh.25120","article-title":"Systematic detection of portal or splenic vein thrombosis after splenectomy for immune cytopenia","volume":"93","author":"Morbieu","year":"2018","journal-title":"Am J Hematol"},{"issue":"1","key":"2021052015231448400_B62","first-page":"72","article-title":"Efficacy and safety of splenectomy in immune thrombocytopenic purpura: long-term results of 402 cases","volume":"90","author":"Vianelli","year":"2005","journal-title":"Haematologica"},{"issue":"5","key":"2021052015231448400_B63","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1365-2141.2010.08377.x","article-title":"Autologous 111 In-labelled platelet sequestration studies in patients with primary immune thrombocytopenia (ITP) prior to splenectomy: a report from the United Kingdom ITP Registry","volume":"151","author":"Sarpatwari","year":"2010","journal-title":"Br J Haematol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/20\/2736\/1807463\/bloodbld2021010968.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/137\/20\/2736\/1807463\/bloodbld2021010968.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T11:23:58Z","timestamp":1621509838000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/137\/20\/2736\/475696\/How-I-treat-primary-ITP-in-adult-patients-who-are"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,20]]},"references-count":63,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2021,5,20]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2021010968","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,20]]}}}